Self-Limited Epilepsy with Autonomic Seizures

1. Disease Information

Overview

Self-limited epilepsy with autonomic seizures (SeLEAS) is a childhood-onset focal epilepsy syndrome in which the seizures are dominated by autonomic manifestations — above all vomiting — rather than by motor or sensory features. It affects otherwise normal children, typically between ages 3 and 6, produces very few seizures overall (often only one), and remits spontaneously within a couple of years. Its clinical signature is a strange one for epilepsy: a fully conscious child who starts retching, goes pale, and then over the next half hour drifts into unresponsiveness with the eyes deviated to one side, most often out of sleep.

The MONDO definition (retrieved from OLS4, 2026-08-05):

"A childhood-onset self-limited focal epilepsy syndrome characterized by the onset in early childhood of focal autonomic seizures that are often prolonged. The EEG commonly shows high amplitude focal spikes typically activated by sleep. Seizures are infrequent in most patients. Seizures are self-limiting with remission typically within a few years from onset."

The 2006 international consensus definition (Ferrie et al., PMID:16483404) is the one most cited in the clinical literature:

"We conclude that PS is a common idiopathic, benign seizure disorder of childhood, which should be classified as an autonomic epilepsy, rather than an occipital epilepsy."

Covanis (PMID:16950946) quotes the consensus wording directly:

"An expert consensus has defined Panayiotopoulos syndrome as 'a benign age-related focal seizure disorder occurring in early and mid-childhood. It is characterized by seizures, often prolonged, with predominantly autonomic symptoms, and by an EEG [electroencephalogram] that shows shifting and/or multiple foci, often with occipital predominance.'"

Key identifiers

Synonyms and alternative names

From MONDO (OLS4) plus the literature:

• Panayiotopoulos syndrome (the eponym; still overwhelmingly dominant in the literature)
• SeLEAS (abbreviation)
• Benign childhood occipital epilepsy, Panayiotopoulos type
• Early-onset benign childhood occipital epilepsy (EBOE)
• Early-onset benign occipital epilepsy
• Benign childhood epilepsy with occipital paroxysms, early-onset variant
• Benign childhood autonomic epilepsy
• Idiopathic childhood occipital epilepsy of Panayiotopoulos

Deprecated terminology to avoid: "benign" and "idiopathic". Quito-Betancourt & Reyes Valenzuela (PMID:37714124) state: "Using the term 'benign' to refer to them is no longer recommended, as this would ignore the comorbidities some individuals suffer. Also, the term 'idiopathic' is now only used to refer to the syndromes classified as Idiopathic Generalized Epilepsies."

Source of information

Almost entirely aggregated disease-level and cohort-level clinical sources: hospital-based prospective and retrospective case series (Caraballo n=192, PMID:17442007; Specchio n=93, PMID:20528983; Değerliyurt n=38, PMID:24840752), an international expert consensus (PMID:16483404), and ILAE nosology documents. There are no EHR-derived phenotype studies, no disease registries, and no population biobank analyses specific to SeLEAS. The one population-based incidence study (PMID:29571057) used prospective clinician reporting within a defined UK/Welsh catchment area, not EHR extraction.

2. Etiology

Disease causal factors

Primary cause: unknown; presumed age-dependent maturational. The dominant framing across three decades of literature is that SeLEAS is not caused by a lesion or a single gene but by a transient, developmentally timed state of cortical hyperexcitability that preferentially engages autonomic circuitry. Panayiotopoulos himself (PMID:15145296) put it this way:

"Pathophysiology of Panayiotopoulos syndrome is unknown, but it is likely that they are due to diffuse maturation-related epileptogenicity activating susceptible-for-children emetic centers and the hypothalamus."

Covanis (PMID:16950946) frames it as one pole of a shared childhood susceptibility:

"Panayiotopoulos syndrome is probably the early-onset and Rolandic epilepsy the late-onset phenotype of a maturation-related benign childhood seizure-susceptibility syndrome."

Structural etiology is exclusionary. Per the ILAE 2022 diagnostic criteria table, "Structural cause for the epilepsy" on imaging is an exclusionary criterion. Note however that Panayiotopoulos (PMID:15145296) reported that among children with autonomic seizures and autonomic status epilepticus generally, "10-20% are due to cerebral pathology" — those cases are symptomatic focal epilepsy, not SeLEAS.

A boundary case worth curating: Cooper et al. (PMID:35871494) found that children with cerebral palsy from prenatal/perinatal vascular injury frequently develop an electroclinically identical picture, which they termed "self-limited focal epilepsy-variant" precisely because the current ILAE classification forbids the diagnosis in the presence of a brain lesion:

"Fifty-six (60%) children with seizures had electroclinical features of a self-limited focal epilepsy of childhood; we diagnosed these children with a self-limited focal epilepsy-variant given the current International League Against Epilepsy classification precludes a diagnosis of self-limited focal epilepsy in children with a brain lesion. … Self-limited focal epilepsy-variant usually manifested with a mix of autonomic and brachio-facial motor features, and occipital and/or centro-temporal spikes on EEG."

This is mechanistically informative: it suggests the autonomic-seizure phenotype reflects an age-dependent network state that a structural lesion can also unmask, rather than a lesion-free requirement of the mechanism itself.

Risk factors — genetic

• No established causal gene. ILAE syndrome page (epilepsydiagnosis.org, CC BY-SA 4.0, text last updated 2024-06-30): "There are no established genes, outside of rare case reports, and no clear indication to perform genetic testing."
• No classical inheritance pattern. ILAE: "There is a higher prevalence of febrile seizures in first degree relatives, suggesting genetic factors play a role, but there is no classical inheritance pattern."
• SCN1A is the one gene with credible (rare) evidence. Kivity et al. (PMID:28192756) described a large GEFS+ family segregating a heterozygous pathogenic SCN1A missense variant in which four members had Panayiotopoulos syndrome: "A pathogenic heterozygous SCN1A (c.2624C>A; p.Thr875Lys) variant was identified. Sixteen of the 18 variant positive family members were affected (88% penetrance): 8 with febrile seizures, 2 febrile seizures plus, 1 unclassified seizures and 5 with self-limited focal epilepsy of childhood. Of these, one was diagnosed with atypical childhood epilepsy with centrotemporal spikes and four with Panayiotopoulos syndrome." Their conclusion: "the GEFS+ spectrum can extend to the self-limited focal epilepsies of childhood, including Panayiotopoulos syndrome."
• Family history of febrile seizures and epilepsy is enriched. Değerliyurt et al. (PMID:24840752): "We found high rates of personal history of febrile convulsions, breath-holding spells, and family history of febrile convulsions, afebrile convulsion/epilepsy, migraine, and breath-holding spells."
• Twin data argue against a simple genetic model. Taylor et al. (PMID:18669497), a twin and multiplex family study of benign occipital epilepsies of childhood: "Monozygotic twin pairs did not show a higher concordance rate than dizygotic twin pairs suggesting that BOEC may not be a purely genetic disorder. … Clinical genetic studies highlight the multifactorial aetiology of BOEC as monozygotic twins have low concordance suggesting that non-conventional genetic influences or environmental factors play a major role." This is the single most important genetic-etiology citation for the entry — it is a direct, human, evidence-based argument against over-genetic framing.
• Complex/polygenic architecture is the working model for self-limited focal epilepsies generally. Tsai et al. (PMID:23294109), studying the related epilepsy-aphasia spectrum and BECTS families, found: "The frequencies of seizures in relatives of probands with EAS suggest that the underlying genetic influence of EAS is consistent with complex inheritance and similar to BECTS."

Risk factors — environmental

NOT AVAILABLE / largely negative. No toxin, infection, occupational, or dietary risk factor has been established. Specifically:

• Antecedent and birth history are normal (ILAE syndrome page).
• Sex: no risk difference. ILAE: "Both sexes are affected equally."
• Age: the only robust "risk factor" is being in the 3–6 year window. This is the defining feature, not an incidental one.
• Prior febrile seizures: present in 5–17% of patients (ILAE syndrome page) — plausibly a shared-susceptibility marker rather than a cause.
• Sleep is a powerful precipitant (not a cause): two-thirds to >80% of seizures arise from sleep (see §3).

Protective factors

NOT AVAILABLE. No protective genetic variant, dietary factor, or lifestyle exposure has been reported for SeLEAS. The condition remits spontaneously regardless of treatment, which makes protective-factor studies both difficult and low-priority.

Gene–environment interactions

NOT AVAILABLE in any direct form. The strongest indirect statement is Taylor et al.'s twin-discordance finding (PMID:18669497) implying that "non-conventional genetic influences or environmental factors play a major role" — i.e. the field explicitly posits a G×E or epigenetic contribution but has not identified it.

3. Phenotypes

3.1 The cardinal phenotype — focal autonomic seizures

The single mandatory seizure type per ILAE 2022. Covanis (PMID:16950946) gives the canonical description:

"Autonomic epileptic seizures and autonomic status epilepticus are the cardinal manifestations of Panayiotopoulos syndrome. Autonomic seizures in Panayiotopoulos syndrome consist of episodes of disturbed autonomic function with emesis as the predominant symptom. Other autonomic manifestations include pallor (or, less often, flushing or cyanosis), mydriasis (or, less often, miosis), cardiorespiratory and thermoregulatory alterations, incontinence of urine and/or feces, hypersalivation, and modifications of intestinal motility."

Suggested HP terms (all verified against OLS4, 2026-08-05):

3.2 Phenotype table with frequencies

3.3 Cognitive and behavioral phenotypes — the "benign" caveat

This is the section where the old "benign" label has been most substantially revised, and it deserves careful curation because the evidence is genuinely split.

Evidence for cognitive comorbidity. Fonseca Wald et al. (PMID:32608507, n=18, Netherlands):

"Mean full-scale IQ (93.5; range 76-123; p=0.04) and performance IQ (93.2; range 76-126; p=0.04) were within the normal range, although significantly lower compared to the normative mean. … Simple auditory/visual reaction times, visual attention, visual-motor integration, and verbal memory were significantly lower compared to normative values. On average, patients with Panayiotopoulos syndrome were 8 months behind in arithmetic speed and 11 months behind in reading speed for the number of months in school. Behavioural questionnaires revealed significantly higher scores on reported internalizing behavioural problems."

Akca Kalem et al. (PMID:31398558, n=20 PS vs 20 Gastaut vs 20 controls):

"With regard to intelligence, the patients with PS scored less in all scales compared to the healthy controls. … Verbal memory problems were eminent in both of the patient groups; whereas, visual memory was impaired only in the group with PS. … Cognitive dysfunction is a more prominent and widespread feature of the patients with PS; whereas, the patients with GS suffer only from milder and isolated cognitive problems."

Hodges et al. (PMID:26709104, n=3): "Neuropsychological findings suggest that the patients had notable impairments on visual memory tasks, especially in comparison with verbal memory. … Academically, the patients were weak in numerical operations and spelling."

Evidence against clinically meaningful comorbidity. Specchio et al. (PMID:20528983, n=93 — by far the largest neuropsychologically characterized cohort):

"On neuropsychological testing, IQ and subtests of Wechsler Intelligence Scale for Children-Revised (WISC-R) were within normal limits, although some minor statistically significant differences were found in arithmetic, comprehension, and picture arrangement in comparison with controls."

And the ILAE syndrome page still states flatly: "Development and cognition are normal."

Curation recommendation: model this as a mild, contested phenotype with an explicit KNOWLEDGE_GAP discussion. The disagreement is real and traceable to cohort size and referral bias (the small tertiary-center cohorts find deficits; the large consecutive-referral cohort does not). A published commentary exists specifically on this question (Wilson, "Rethinking neurobehavioral comorbidity in Panayiotopoulos syndrome", PMID:31909486).

Suggested HP terms for this cluster: - Specific learning disability — HP:0001328 - Impaired visuospatial constructive cognition — HP:0010794 - Attention deficit hyperactivity disorder — HP:0007018 (weakly supported; Akca Kalem found no behavioral excess) - Anxiety — HP:0000739 (internalizing problems, PMID:32608507)

3.4 Onset, severity, progression

• Age of onset: 3–6 years in ~70%; full range 1–14 years (ILAE syndrome page). Specchio: "Age at onset ranged from 1.1 to 8.6 years, and was earlier in children with more than one seizure" (PMID:20528983). Caraballo: "PS had a peak age at onset of 5 years" (PMID:17442007). Değerliyurt: "Seizures started before the age of eight in 87% of the patients, and the mean age at seizure onset was 4.6 years" (PMID:24840752).
• Severity: individually dramatic, cumulatively mild. Single seizures are frightening and often prolonged, but total seizure burden is low.
• Progression: episodic and self-limiting. Not progressive. ILAE: "Seizures usually remit in 1-2 years."
• Seizure count: ILAE: "Seizure frequency is usually low, 25% of children have only a single seizure and most children have ≤5 seizures in total." Caraballo (PMID:17442007): "Eighty-four (44.2%) had a single seizure, 79 (41.2%) had 2-5 fits, and 28 (14.6%) had frequent seizures." Tedrus (PMID:17057874): "Fourteen children (38.8%) had a single seizure."

3.5 Quality of life impact

Limited direct evidence. No SeLEAS-specific EQ-5D, SF-36, PROMIS, or QOLCE study exists. What is available:

• The dominant QoL burden is diagnostic, not seizure-related. Graziosi et al. (PMID:31369969): "a wrong diagnosis may lead to inappropriate interventions. The consequences are high morbidity, costly mismanagement, and stress for children and their parents." Covanis (PMID:16950946) echoes: "The consequence is avoidable misdiagnosis, high morbidity, and costly mismanagement." Children are subjected to lumbar punctures, empiric aciclovir, ICU admission, and repeated imaging for a condition that requires none of it.
• Academic impact (PMID:32608507): reading and arithmetic speed lag by 8–11 school months; "Mild-to-severe academic underachievement was present in more than half of the children with Panayiotopoulos syndrome."
• A single lateralization-based QoL study in childhood epilepsy (not SeLEAS-specific) found right-hemispheric foci associated with worse anxiety/social/stigma scores (PMID:20716372) — mark as indirect.
• A pilot exercise-therapy trial in the sibling syndrome BECTS (PMID:25025685) showed improvement in internalizing behavioral problems and mood-related well-being; not performed in SeLEAS.

4. Genetic / Molecular Information

Causal genes

NONE ESTABLISHED. This is the correct curation, and it should be stated affirmatively rather than left blank. Authoritative statement (ILAE, epilepsydiagnosis.org, June 2024): "There are no established genes, outside of rare case reports, and no clear indication to perform genetic testing."

Candidate / reported genes

The critical framing sentence from the exome study (Rudolf et al., PMID:32600977): "Our results further illustrate the fact that atypical SFEC are more likely to have Mendelian inheritance than typical SFEC." In other words — the more the child looks like textbook SeLEAS, the less likely a gene will be found. This should be recorded as a curation-relevant principle, not just a result.

Variant classification, type, allele frequency, origin, functional consequence

• Classification: the SCN1A p.Thr875Lys variant is reported as pathogenic (PMID:28192756); no other variant is classified for this syndrome. No ClinVar assertion set exists for "Panayiotopoulos syndrome" as a condition.
• Type: missense (SCN1A); the candidate set includes null, missense, and splice-site variants.
• Allele frequency: NOT AVAILABLE — no population-frequency analysis has been performed against a SeLEAS phenotype.
• Somatic vs germline: all reported variants are germline. No somatic/mosaic mechanism has been proposed.
• Functional consequence: for SCN1A, the GEFS+ mechanism is generally loss of function of Na_v1.1 in GABAergic interneurons producing disinhibition — but this is extrapolated from GEFS+/Dravet biology, not demonstrated for the SeLEAS phenotype. Mark as inference.

Modifier genes

NOT AVAILABLE. No modifier gene has been identified. Because SeLEAS remits regardless, there is no severity gradient to map modifiers against.

Epigenetic information

NOT AVAILABLE. No methylation, histone-modification, or chromatin study exists for SeLEAS. Rudolf et al. (PMID:32600977) noted "missense variants in genes encoding enzymes involved in chromatin remodeling" among candidates in atypical self-limited focal epilepsies — a hint, not a finding.

Chromosomal abnormalities

NOT AVAILABLE / negative. No recurrent CNV, translocation, or aneuploidy is associated. Chromosomal microarray is not indicated for typical SeLEAS.

5. Environmental Information

• Environmental factors: NOT AVAILABLE. No toxin, radiation, pollution, or occupational exposure has been linked.
• Lifestyle factors: NOT AVAILABLE. No dietary, smoking (obviously), alcohol, or activity association. Sleep is a precipitant of individual seizures (two-thirds occur in sleep, PMID:16950946), and sleep deprivation activates the EEG abnormality (ILAE EEG page) — curate these as seizure precipitants, not disease-causing environmental factors.
• Infectious agents: NOT AVAILABLE as cause. The clinically important relationship is the reverse: SeLEAS is repeatedly mistaken for CNS infection. Covanis (PMID:16950946): "The clinical features of Panayiotopoulos syndrome are frequently mistaken as nonepileptic conditions such as acute encephalitis, syncope, migraine, cyclic vomiting syndrome, motion sickness, sleep disorder, or gastroenteritis." Note also that fever is uncommon in SeLEAS and is a useful discriminator: Kawakami et al. (PMID:35153087) found fever in "all patients with acute encephalopathy (100%), but less frequently in those with PS (11%, P < 0.001)."

6. Mechanism / Pathophysiology

This is where curation needs the most discipline. There is a well-articulated, widely repeated hypothesis, and essentially no molecular data. Below is the causal chain as the field states it, with each link labelled by evidence strength.

6.1 The proposed causal chain

Trigger (upstream) → Consequence (downstream):

1. Age-dependent, diffuse cortical hyperexcitability (maturational, cause unknown) ↓
2. Ictal discharge of variable lobar onset — critically, not fixed to occipital cortex ↓
3. Propagation to / engagement of the central autonomic network (insula, anterior cingulate, amygdala, hypothalamus, brainstem autonomic nuclei), which in this age group has a lower seizure threshold than cortex ↓
4. Autonomic output discharge — emetic-center activation, sympathetic/parasympathetic imbalance, hypothalamic thermoregulatory and cardiorespiratory involvement ↓
5. Clinical autonomic seizure: emesis, pallor, mydriasis, thermoregulatory and cardiorespiratory change, ictal syncope ↓
6. Optional further cortical propagation → impaired awareness, eye deviation, hemi- or bilateral convulsions (only ~50% of seizures) ↓
7. Age-dependent resolution of the underlying hyperexcitable state → remission by early-to-mid adolescence

6.2 Evidence for each link

Link 1 (maturational hyperexcitability) — moderate, inferential. Panayiotopoulos (PMID:15145296): "it is likely that they are due to diffuse maturation-related epileptogenicity activating susceptible-for-children emetic centers and the hypothalamus." Covanis (PMID:16950946) adds the childhood-specificity argument: "The symptoms/sequence of autonomic seizures and autonomic status epilepticus in Panayiotopoulos syndrome are specific to childhood, and they do not occur in adults." That is a strong, testable claim — the same discharge in an adult brain does not produce this phenotype.

Link 2 (variable lobar onset) — strong. Koutroumanidis (PMID:17441996): "Clinically, PS is manifested by predominantly autonomic seizures and electrographically with multifocal interictal spikes, while the few published ictal recordings have documented onsets of variable lobar topography. These typical electroclinical features do not allow straightforward assignment to a distinctive cortical area, rendering the term 'focal'—as we currently understand it—problematic." He proposes SeLEAS as a model "system epilepsy" — the epilepsy of a functional system rather than of a place. Specchio confirms with ictal data: "Onsets in five ictal EEGs were posterior or anterior-left or right" (PMID:20528983).

Link 3 (central autonomic network with lower threshold) — moderate, mostly review-level. Zontek & Paprocka (PMID:35740751) is the dedicated review: "The purpose of this review is to underline the role of central autonomic network dysfunction in the development of Panayiotopoulos syndrome, as well as the possibility of using functional imaging techniques, especially functional magnetic resonance imaging (fMRI), in the diagnostic process. These methods could be crucial for understanding the pathogenesis of PS." Note the tense: could be — the fMRI work has been proposed, not done. Tata et al. (PMID:24777033) provide comparative electroclinical support: "Panayiotopoulos syndrome differs from symptomatic occipital lobe epilepsy and has a unique low epileptogenic threshold related to particular brain circuits."

Link 4/5 (autonomic output) — strong at the descriptive level, absent at the molecular level. Every large series documents the output. Nobody has measured the mediators in SeLEAS patients specifically.

Link 7 (age-dependent remission) — strong, and now with an EEG correlate. Oguni's EEG reappraisal (PMID:37660659) maps a spatially migrating, age-locked evolution — the mechanism leaves fingerprints as it matures out:

"The interictal EEG characteristics of SeLEAS are multifocal EEG foci with age-dependent predominant locations; occipital (O) at 2-5 years old, and occipital and frontopolar (synchronous and independent O and Fp spikes) at 4-7 years old and centro-parieto-temporal (CPT) at 6-10 years old. O EEG foci evolve to multifocal EEG foci with a O-Fp or CPT predominance with age and disappear by 12∼16 years old."

That migrating focus is arguably the best single piece of mechanistic evidence in the whole literature: whatever is hyperexcitable is not anatomically fixed, and it moves on a developmental clock.

6.3 Cellular processes, molecular pathways, protein dysfunction, metabolism, immunity, tissue damage

• Molecular pathways: NOT AVAILABLE. No KEGG/Reactome pathway has been implicated by data. If SCN1A is invoked (rare cases only), the relevant processes would be sodium-channel-dependent action potential generation and interneuron-mediated inhibition.
• Cellular processes: inferred only — excitation/inhibition imbalance in cortical and subcortical circuits.
• Protein dysfunction: NOT AVAILABLE except in the rare SCN1A families.
• Metabolic changes: NOT AVAILABLE. No metabolic abnormality; metabolic disease is in fact a differential diagnosis to exclude (ILAE lists "metabolic disorders (especially mitochondrial)" as a differential).
• Immune involvement: NOT AVAILABLE / not implicated. SeLEAS is not autoimmune. (For contrast, one pediatric study found elevated anti-GAD antibodies in children with encephalitis and status epilepticus — PMID:22964438 — but this concerns the differential-diagnosis population, not SeLEAS.)
• Tissue damage mechanisms: NONE. This is a positive, important finding for the entry. Covanis (PMID:16950946): "Autonomic status epilepticus imparts no residual neurologic deficit." Specchio (PMID:20528983) confirms that prolonged seizures do not worsen outcome: "More than half (55%) of seizures were longer than 30 min but these did not appear to affect remission and number of seizures." SeLEAS is one of the few conditions in which >30-minute status epilepticus is repeatedly shown to be harmless.
• Biochemical abnormalities: NOT AVAILABLE. No enzyme deficiency, no receptor defect, no established channelopathy.
• Epigenetic changes: NOT AVAILABLE.

6.4 Molecular profiling and advanced technologies

ALL NOT AVAILABLE. No transcriptomics, proteomics, metabolomics, lipidomics, single-cell, spatial, multi-omics, or CRISPR/RNAi screen has been performed on SeLEAS. GEO/ArrayExpress/PRIDE/MetaboLights contain no SeLEAS-specific dataset. This should be curated as an explicit knowledge gap, not silently omitted.

The one emerging quantitative biomarker is electrophysiological, not molecular. Fujita et al. (PMID:37918221) studied scalp-recorded high-frequency oscillations:

"Thirteen patients (72.2%) had HFOs while five patients (27.8%) had no HFOs in 194 interictal EEG records. … the seizure activity period of the HFOPG was significantly longer than that of the HFONG. Patients with an HFO duration longer than 2 years were intractable to treatment. In most cases, seizures did not occur in the absence of HFOs, even when the spikes remained. … We propose that HFOs are a biomarker of epileptogenicity and an indicator for drug reduction because seizures did not occur if HFOs disappeared even if the spikes remained."

6.5 Suggested ontology terms for mechanism nodes

GO biological processes (verified via OLS4; use with modifier since none are defective in a demonstrated sense):

CL cell types (all inferred, not demonstrated — flag as such): - cerebral cortex neuron — CL:0010012 - pyramidal neuron — CL:0000598 - GABAergic interneuron — CL:0011005 - astrocyte — CL:0000127 (speculative; include only if a mechanism node requires it)

7. Anatomical Structures Affected

Organ level

• Primary organ: brain — UBERON:0000955. Specifically cerebral cortex — UBERON:0000956.
• Body systems involved: central nervous system (primary); autonomic nervous system (the functional target); cardiovascular and gastrointestinal systems (as autonomic output organs, not as sites of disease).
• Secondary organ involvement: none structurally. Heart and lungs are affected only transiently and functionally during seizures (bradycardia, apnea, in exceptional cases arrest).

Regional / tissue level

For general context on the network, Edlow et al. (PMID:26530629) mapped the human central homeostatic network structurally: "interconnected brainstem and forebrain nodes form an integrated central homeostatic network (CHN) in the human brain." This is a healthy-adult connectome study, not SeLEAS — cite as background only.

Cell and subcellular level

• Cell populations: not demonstrated. See §6.5 for inferred CL terms.
• Subcellular compartments: NOT AVAILABLE. No GO Cellular Component involvement has been established. If SCN1A cases are modeled, plasma membrane / axon initial segment would apply — mark as inference.

Localization and lateralization

• Multifocal and shifting — the defining spatial property. ILAE EEG page: "Multifocal high voltage spikes or sharp-waves are typically seen, these often are present in different focal areas on sequential EEGs. All focal brain regions may be affected but abnormality is often over the posterior (occipital) regions."
• Bilateral involvement over time, unilateral per event. ILAE: "Ictal patterns are unilateral, often having posterior onset."
• Persistent unifocal abnormality is an ILAE ALERT criterion — i.e. a focus that stays put suggests a structural lesion, not SeLEAS.

8. Temporal Development

Onset

• Typical age: 3–6 years (~70% of cases); range 1–14 years (ILAE syndrome page).
• Peak: 5 years (PMID:17442007); mean 4.6 years (PMID:24840752).
• Onset pattern: acute/paroxysmal at the level of the individual seizure; the epilepsy itself begins abruptly with a first, often dramatic and prolonged, event. There is no prodrome and no insidious phase.
• Earlier onset predicts more seizures: "Age at onset ranged from 1.1 to 8.6 years, and was earlier in children with more than one seizure" (PMID:20528983).

Progression and course

• Course pattern: episodic, self-limited. Not progressive, not relapsing-remitting in the immunological sense.
• Total duration of active epilepsy: typically 1–2 years (ILAE syndrome page).
• Remission: spontaneous and age-determined. ILAE course-of-illness criterion: "Remission by early to mid adolescence. No regression." ILAE clarifies the term: "Self-limiting refers to there being a high likelihood of seizures spontaneously remitting at a predictable age."
• EEG normalizes later than the clinical course: spikes "disappear by 12∼16 years old" (PMID:37660659) — expect EEG abnormality to outlast seizures, and do not treat the EEG.
• Recurrence kinetics (Specchio, PMID:20528983): "Cumulative probability of recurrence was 57.6%, 45.6%, 35.1%, and 11.7% at 6, 12, 24, and 36 months, respectively, after the first seizure." — a clean, curatable natural-history curve.

Evolution to other syndromes

• To SeLECTS (Rolandic epilepsy): ILAE: "Some patients may evolve to have self-limited epilepsy with centrotemporal spikes." Caraballo (PMID:17442007): "Sixteen children had concomitant symptoms of rolandic epilepsy and eight developed rolandic seizures after remission of PS seizures."
• To DEE-SWAS / electrical status epilepticus in sleep — rare but the key adverse outcome. Değerliyurt (PMID:24840752): "Evolution to electrical status epilepticus in sleep and Gastaut-type epilepsy were seen in patients with more than ten seizures." Oguni (PMID:37660659): "O-Fp EEG foci may further evolve to generalized spike-wave complexes and rarely to spike-wave activated in sleep." Semprino (PMID:35063695) reports one such patient. Per ILAE, "Regression with spike-wave activation in sleep (consider DEE-SWAS)" is both an ALERT and a course-of-illness EXCLUSIONARY criterion.
• Mixed PS/Gastaut phenotypes are common. Taylor et al. (PMID:18669497): "One-third of the children in this selected series of BOEC did not have a pure syndrome, rather a mixed syndrome with features of both Panayiotopoulos and Gastaut syndromes. … BOEC is an electro-clinical spectrum with Panayiotopoulos and Gastaut syndromes at either end."

Critical periods

The 3–6 year window is the vulnerability period; adolescence is the resolution period. There is no intervention window in the disease-modifying sense — treatment does not alter the timeline. Specchio (PMID:20528983): "Thirty-four (58.6%) of 59 patients treated with antiepileptic drugs continued having seizures before ultimate remission."

9. Inheritance and Population

Epidemiology

Two very different-looking numbers circulate, and they measure different things. Curate both, clearly separated.

Proportion of childhood afebrile seizures (a fraction, not a rate):

Covanis (PMID:16950946): "Panayiotopoulos syndrome probably affects 13% of children aged 3 to 6 years who have had 1 or more afebrile seizures and 6% of such children in the 1- to 15-year age group." Panayiotopoulos (PMID:15145296) gives the same figures: "They probably affect approximately 13% of children aged 3-6 years with one or more nonfebrile seizures, or 6% in the age group 1-15." Graziosi (PMID:31369969) restates: "a frequent (6% among children of 1-15 years) and benign epileptic syndrome."

Specchio's consecutive-referral series gives a slightly lower, arguably cleaner figure (PMID:20528983): "Of 1,794 children aged between 1 and 14 years referred for the first afebrile focal seizure, between January 1992 and December 2004, 93 (5.2%) had PS according to clinical criteria."

Population incidence (an actual rate):

Weir et al. (PMID:29571057), the only population-based study: "The incidence of PS and BECTS was found to be 0.8 and 6.1 per 100,000 <16 year olds, respectively. … The findings suggest BECTS is eight times more common than PS and that the incidence of PS is lower than previously suggested."

For dismech Prevalence records, this maps to:

⚠ Curation warning: the widely-quoted "6%" and "13%" are case fractions among children with afebrile seizures, not population prevalence. Encoding them in a Prevalence record with population: Worldwide would be a category error. Put them in notes or model them as a diagnostic-yield statistic.

UK caseload estimate for planning purposes (Mellish et al., PMID:25202134): "We estimated, annually, 751 new RE cases and 233 PS cases" in the UK.

For genetic etiology

• Inheritance pattern: multifactorial / complex. No Mendelian pattern. ILAE: "there is no classical inheritance pattern." HPO mode-of-inheritance term: consider HP:0010982 (Polygenic inheritance) with relationship_type: SUSCEPTIBILITY for any gene, or leave inheritance unbound and describe in prose. Do not assert autosomal dominant.
• Penetrance: N/A for the syndrome. For the one SCN1A family, penetrance of any GEFS+-spectrum phenotype was 88% (16/18), but only 4/18 had the PS phenotype — i.e. penetrance for this specific phenotype was ~22% (PMID:28192756).
• Expressivity: highly variable within the one informative family — febrile seizures, FS+, atypical BECTS, and PS all segregated with the same variant.
• Genetic anticipation: NOT AVAILABLE / not applicable (no repeat expansion mechanism).
• Germline mosaicism: NOT AVAILABLE.
• Founder effects: NOT AVAILABLE.
• Consanguinity: no established role.
• Carrier frequency: NOT APPLICABLE (no recessive mechanism).
• Family history rates: ILAE: "There is a higher prevalence of febrile seizures in first degree relatives and case reports of siblings with other self-limited focal epilepsies of childhood." In the related BECTS comparison cohort, 9.8% of first-degree relatives had seizures (PMID:23294109).

Population demographics

• Sex ratio: 1:1. ILAE: "Both sexes are affected equally." (Contrast with the epilepsy-aphasia spectrum, where male predominance is seen — PMID:23294109.)
• Ethnic/geographic distribution: no population is known to be over- or under-represented. The syndrome has been described in large series from Argentina (n=192, PMID:17442007), Italy (n=93, PMID:20528983), Turkey (n=38, PMID:24840752; n=24, PMID:24777033), Japan (PMID:37660659, PMID:35153087), Brazil (n=36, PMID:17057874), the Netherlands (PMID:32608507), the UK (PMID:29571057), India (PMID:18515936), Saudi Arabia (PMID:21822089), and Germany (PMID:42348808). Panayiotopoulos (PMID:15145296) noted it "has been confirmed worldwide in more than 800 cases." This global spread with no reported hotspot is itself weak evidence against a founder variant.
• Age distribution of affected individuals: essentially all prevalent cases are aged ~1–16 years. Adults do not have this syndrome — Covanis (PMID:16950946) is explicit: the autonomic seizure sequence "do[es] not occur in adults."

10. Diagnostics

10.1 ILAE 2022 diagnostic criteria (verbatim from epilepsydiagnosis.org, CC BY-SA 4.0, text last updated 2024-06-30)

Additional ILAE notes, verbatim:

"An MRI is not mandatory for diagnosis but should be considered in the presence of any alerts" "An ictal EEG is not required" "Syndrome without laboratory confirmation: in resource-limited regions, an interictal EEG is required to diagnose this syndrome" "Alert criteria are absent in the vast majority of patients with the syndrome, but rarely can be seen. Their presence should result in caution in diagnosing the syndrome and consideration of other conditions"

10.2 Electrophysiology — EEG (the only positive test)

Covanis (PMID:16950946): "An electroencephalogram is the only investigation with abnormal results, usually showing multiple spikes in various brain locations."

ILAE EEG description (verbatim): - Background: "The background EEG is normal." Caution: "Focal slowing consistently over one area is not seen — consider structural brain abnormality." - Interictal: "A standard EEG can be normal in some patients. Multifocal high voltage spikes or sharp-waves are typically seen, these often are present in different focal areas on sequential EEGs. All focal brain regions may be affected but abnormality is often over the posterior (occipital) regions." - Activation: "EEG abnormality is enhanced by sleep deprivation, in drowsiness and in sleep, when discharges often have a wider field and may be bilaterally synchronous. Eye closure (elimination of central vision and fixation off sensitivity) may activate posterior discharges in some patients." - Ictal: "Ictal patterns are unilateral, often having posterior onset, with rhythmic slow (theta or delta) activity intermixed with small spikes and/or fast activity."

Quantitative EEG findings from cohorts: - Multifocal epileptiform discharges: 79.5% (PMID:20528983), 84% (PMID:24840752) - Occipital spikes: 75%; rolandic spikes also present in 25%; normal EEG in 16.6% (PMID:17057874) - Consistently normal EEG: 5.4%; background abnormality only: 16.1% (PMID:20528983) - Non-REM sleep activation in both PS and symptomatic occipital epilepsy; in PS the spikes "tended to spread mainly to central and centro-temporal regions" (PMID:24777033) - Age-dependent spatial migration (PMID:37660659): occipital at 2–5 y → occipital + frontopolar at 4–7 y → centro-parieto-temporal at 6–10 y → gone by 12–16 y. Oguni proposes: "O-Fp EEG foci may be a specific EEG pattern indicating a diagnosis of SeLEAS." - Emerging: interictal scalp HFOs as an activity biomarker (PMID:37918221) — 72.2% HFO-positive; HFO duration >2 years predicted treatment-refractoriness; "seizures did not occur if HFOs disappeared even if the spikes remained."

NCIT term: Electroencephalography — NCIT:C38054

10.3 Imaging

Normal, and often unnecessary. ILAE: "Neuroimaging is normal. If the clinical presentation and EEG is typical for this syndrome, imaging is not required."

Mellish et al. (PMID:25202134) documented over-imaging in UK practice: "MRI brain at least half the time in 40%-65% cases … Management among respondents is broadly in line with national guidance, although with possible overuse of brain imaging and underuse of EEG and neuropsychological assessments."

NCIT term: Magnetic Resonance Imaging — NCIT:C16809

10.4 Laboratory tests, biomarkers, biopsy, pathology

ALL NORMAL / NOT AVAILABLE. There is no blood, urine, CSF, or tissue abnormality. No biomarker exists. No histopathology exists (no one biopsies this). The main laboratory issue is avoiding unnecessary invasive testing — see the misdiagnosis literature below.

10.5 Genetic testing

Not indicated for typical cases. ILAE: "There are no established genes, outside of rare case reports, and no clear indication to perform genetic testing."

Reasonable exceptions, based on Rudolf et al.'s finding that "atypical SFEC are more likely to have Mendelian inheritance than typical SFEC" (PMID:32600977): - Atypical presentation (regression, spike-wave activation in sleep, drug resistance, alert criteria present) → epilepsy gene panel or WES may be considered, including SCN1A and GRIN2A. - Strong family history of GEFS+-spectrum phenotypes → SCN1A testing may be considered (PMID:28192756). - WGS, CMA, karyotype, FISH, mtDNA testing, repeat expansion testing: not indicated.

10.6 Omics-based diagnostics

NONE AVAILABLE OR INDICATED. No RNA-seq, proteomic, metabolomic, epigenomic, or liquid-biopsy assay is used or under development for SeLEAS.

10.7 Differential diagnosis

ILAE list (verbatim): - "Focal autonomic seizures due to structural brain abnormality" - "Migraine associated disorders including benign paroxysmal vertigo" - "Disorders associated with intermittent encephalopathy e.g. metabolic disorders (especially mitochondrial)" - "Disorders associated with intermittent vomiting e.g. gastrointestinal disorders"

Extended literature list with distinguishing features:

The framing sentence for the entry (Parisi et al., PMID:17464469): "The peculiar aspects should be known not only by epileptologists but also by general doctors because a correct diagnosis would avoid aggressive interventions and concerns on account of its benign outcome."

10.8 Screening

NOT APPLICABLE. No newborn screening, carrier screening, or cascade screening exists or is warranted. Graziosi et al. (PMID:31369969) do make a service-level suggestion: "The availability of electroencephalography (EEG) recording in pediatric Emergency Departments might be useful for a prompt and not-cost-consuming diagnosis."

11. Outcome / Prognosis

Survival and mortality

• Life expectancy: normal. No excess mortality attributable to SeLEAS has been demonstrated in any cohort.
• Disease-specific mortality: no deaths from SeLEAS are reported in the major series (Caraballo n=192, Specchio n=93, Değerliyurt n=38, Tedrus n=36 — zero deaths across all).
• The one theoretical risk is ictal cardiorespiratory arrest. Covanis (PMID:16950946): "Cardiorespiratory arrest is exceptional" and "autonomic seizures are potentially life-threatening in the rare context of cardiorespiratory arrest, an area in which additional study is required."
• Mujawar et al. (PMID:21822089): "ictal cardiorespiratory arrest is extremely rare, with only 4 cases being reported in literature. All 4 cases reported in literature recovered spontaneously and did not require resuscitation. Here we present a 3½-year-old male child with Panayiotopoulos syndrome who presented with status epilepticus and ictal cardiorespiratory arrest requiring cardiopulmonary resuscitation for revival."
• Yamamoto et al. (PMID:29926008), a 10-year-old resuscitated after ictal cardiac arrest: "Lifethreating cardiopulmonary arrest is rare in PS, but long seizure duration of PS may associate with apnea and bradycardia."
• Semprino et al. (PMID:35063695): 2/44 patients in an atypical-presentation series — "Two children (4.8%) had their first seizure while asleep associated with cardiorespiratory arrest." Note the denominator is enriched for atypia.
• A second, iatrogenic mortality pathway is explicitly flagged. Covanis (PMID:16950946): "Autonomic status epilepticus in the acute stage needs thorough evaluation; aggressive treatment may cause iatrogenic complications including cardiorespiratory arrest." Over-treating this condition can hurt the child more than the condition does. This belongs in the entry as a treatment-safety node.

Morbidity and function

• No residual neurological deficit. Covanis (PMID:16950946): "Autonomic status epilepticus imparts no residual neurologic deficit."
• Risk of adult epilepsy is not elevated. Covanis: "The risk of epilepsy in adult life seems to be no higher than in the general population."
• Possible mild cognitive/academic morbidity — see §3.3. Contested. The strongest claim (PMID:32608507): "Mild-to-severe academic underachievement was present in more than half of the children with Panayiotopoulos syndrome." The largest cohort (PMID:20528983) does not support clinically meaningful impairment.
• QoL measures: no disease-specific instrument data. See §3.5.

Disease course and complications

• Complications: autonomic status epilepticus (common, benign); evolution to DEE-SWAS or Gastaut syndrome (rare, associated with >10 seizures — PMID:24840752); ictal cardiorespiratory arrest (exceptional); misdiagnosis-driven iatrogenic harm (common and underappreciated).
• Recovery potential: complete, with or without treatment. Mujawar (PMID:21822089): "Recovery from this autonomic status epilepticus is within hours and is always complete."

Prognostic factors

Overall summary (Specchio, PMID:20528983): "PS is a uniform childhood susceptibility to autonomic seizures that is related to early age of development and with excellent prognosis with regard to seizure remission and neuropsychological development."

12. Treatment

12.1 The central treatment fact: often, no treatment

Covanis (PMID:16950946): "Education about Panayiotopoulos syndrome is the cornerstone of management. Prophylactic treatment with antiepileptic medication may not be needed for most patients."

Vigevano et al. (PMID:23622206), on self-limited focal epilepsies generally: "These entities are age-dependent and seizures tend to disappear spontaneously. For these reasons often the drug treatment is not necessary."

UK practice reality (Mellish et al., PMID:25202134): "Clinicians reported non-treatment in 40%: main reasons were low frequency of seizures and parent/child preferences."

Efficacy caveat — treatment does not reliably prevent seizures either (Specchio, PMID:20528983): "Thirty-four (58.6%) of 59 patients treated with antiepileptic drugs continued having seizures before ultimate remission." And most patients who are treated need only one drug (Değerliyurt, PMID:24840752): "Two or more antiepileptic drugs were required in only 13% of the patients."

12.2 Pharmacotherapy

⚠ There is no randomized controlled trial of any drug in SeLEAS. Drug choice is by clinician preference and extrapolation from focal epilepsy. Mellish et al. (PMID:25202134) surveyed UK preference explicitly to design a future trial: "Carbamazepine is the preferred older, and levetiracetam the preferred newer, RCT arm."

Alternative generic term: Anticonvulsant Therapy — NCIT:C64172; Anticonvulsant Agent — NCIT:C264.

The one quantitatively supported acute-treatment finding (Kawakami et al., PMID:35153087): "seizures were treatable in all patients with PS with a small dose of midazolam (0.1 mg/kg), but all patients with acute encephalopathy required midazolam at 0.3 mg/kg or more (P < 0.001)." This doubles as a therapeutic and a diagnostic observation — SeLEAS status is unusually benzodiazepine-responsive.

Safety flag for sodium-channel blockers. Pasini et al. (PMID:35151939) report iatrogenic ictal asystole with carbamazepine and phenytoin: "The clear relationship between ictal arrhythmia and sodium channels blockers may be related to the negative chronotropic and inotropic cardiac effects." Given that SeLEAS already carries a rare ictal-bradycardia/asystole risk, this interaction deserves an explicit note — the cases were in pharmacoresistant focal epilepsy, not SeLEAS, so mark as an extrapolated caution.

12.3 Management of autonomic status epilepticus

Ferrie et al.'s consensus definition (PMID:17442005) is the reference standard:

"Autonomic SE is a condition lasting at least 30 min and characterized by epileptic activity causing altered autonomic function of any type at seizure onset or in which manifestations consistent with altered autonomic function are prominent (quantitatively dominant or clinically important) even if not present at seizure onset. It is best described, and probably most commonly encountered in children, with Panayiotopoulos syndrome. … Its pathogenesis and most appropriate management are poorly understood."

Management principles: evaluate thoroughly, treat gently. Covanis (PMID:16950946): "Autonomic status epilepticus in the acute stage needs thorough evaluation; aggressive treatment may cause iatrogenic complications including cardiorespiratory arrest."

12.4 Pharmacogenomics

NOT AVAILABLE for SeLEAS specifically. The general pediatric epilepsy PGx caveats apply: HLA-B*15:02 screening before carbamazepine in at-risk ancestries (CPIC), and CYP2C9/CYP2C19 effects on phenytoin and valproate metabolism. None is SeLEAS-specific.

12.5 Advanced therapeutics

ALL NOT APPLICABLE. No gene therapy, cell therapy, RNA-based therapy, targeted therapy, or immunotherapy is under development or would be justified for a condition that remits on its own within 1–2 years.

12.6 Surgical and interventional

NOT INDICATED. Epilepsy surgery has no role. The syndrome has no resectable focus (the foci shift), no lesion, and self-resolves. (For context on when surgery is considered in other pediatric epilepsies, see PMID:34620459 — SeLEAS is not among them.)

12.7 Supportive, rehabilitative, and educational

12.8 Experimental treatments and clinical trials

NO REGISTERED TRIALS. A ClinicalTrials.gov API v2 query (query.cond=Panayiotopoulos and query.term=Panayiotopoulos, retrieved 2026-08-05) returned zero studies. Curate clinical_trials: as empty and note the absence explicitly — it is informative, not an omission.

Mellish et al. (PMID:25202134) exist precisely to argue this gap should be closed: "Considerable international variation in management and controversy about non-treatment indicate the need for high quality randomised controlled trials (RCT)… Approximately one-half considered active and placebo designs acceptable, choosing seizures as primary and cognitive/behavioural measures as secondary outcomes."

12.9 Treatment strategy

A defensible algorithm from the literature:

1. Diagnose correctly (clinical picture + interictal EEG). Avoid LP, empiric aciclovir, ICU admission where the picture is typical.
2. Educate the family; provide a written seizure action plan.
3. Provide home rescue medication (benzodiazepine) for seizures lasting >5 min, given that half exceed 30 min.
4. Withhold maintenance ASM in most children — ~40% of UK clinicians do (PMID:25202134); 25% of children have only one seizure ever (ILAE).
5. Start maintenance ASM for frequent seizures (>monthly is an ILAE alert), multiple prolonged episodes, or high family anxiety. First-line by practice preference: carbamazepine/oxcarbazepine or levetiracetam.
6. Withdraw after ~2 seizure-free years; consider HFO disappearance as a supporting indicator (PMID:37918221). Do not treat the EEG — spikes persist until 12–16 years.
7. Re-evaluate the diagnosis if any ILAE alert appears, particularly regression with sleep-activated spike-wave (→ DEE-SWAS).

Personalized medicine approaches: NOT AVAILABLE. No genotype-guided treatment exists.

13. Prevention

• Primary prevention: NOT POSSIBLE / NOT APPLICABLE. No modifiable risk factor exists.
• Secondary prevention (early detection): the meaningful target is prevention of misdiagnosis, not prevention of disease. The concrete proposal in the literature is ED access to EEG (PMID:31369969). Berg et al. (PMID:42348808) add a second detection target: "When evaluating children and adolescents with headache, clinicians should give greater consideration to SeLEAS as a differential diagnosis than in the past, especially due to its significant therapeutic implications."
• Tertiary prevention (complication prevention):
• Rescue benzodiazepine to abort prolonged seizures and reduce autonomic status duration (linked to the apnea/bradycardia risk, PMID:29926008).
• Avoiding over-aggressive acute treatment, which can itself precipitate cardiorespiratory arrest (PMID:16950946).
• Monitoring for evolution to DEE-SWAS in children with >10 seizures (PMID:24840752).
• Immunization: NOT APPLICABLE. No vaccine-preventable component. (There is no evidence linking vaccination to SeLEAS onset either.)
• Screening programs / genetic screening / PGD / prenatal testing: NOT APPLICABLE. No causal gene; recurrence risk is not quantified beyond a general familial enrichment of febrile seizures.
• Risk stratification: NOT AVAILABLE. No validated risk model.
• Behavioral interventions: none established. A single small pilot in the sibling syndrome BECTS suggested structured exercise improved neurocognitive and internalizing-behavior outcomes (PMID:25025685) — hypothesis-generating only, not performed in SeLEAS.
• Counseling: reassurance-focused counseling about excellent prognosis is the highest-value "preventive" act, since the documented harms of this condition are largely those of misdiagnosis and family distress.
• Public health / environmental interventions: NOT APPLICABLE.
• Prophylaxis: maintenance ASM is the only prophylactic option and is explicitly optional (§12).

14. Other Species / Natural Disease

NO NATURAL ANIMAL COUNTERPART IS KNOWN. This should be curated as an explicit negative.

• Taxonomy: Homo sapiens — NCBITaxon:9606 — only.
• Breed (VBO): NOT APPLICABLE.
• Orthologous genes: since no causal gene exists, orthology is moot. If SCN1A is curated as a rare susceptibility gene, orthologs exist (mouse Scn1a, NCBI Gene 20265; zebrafish scn1lab), but they model Dravet/GEFS+ rather than SeLEAS.
• Natural disease in other species: NOT AVAILABLE. No OMIA entry corresponds to SeLEAS. Idiopathic epilepsy is common in dogs (many breeds) but no canine syndrome with age-dependent autonomic/emetic seizures and spontaneous remission has been characterized as a SeLEAS analog.
• Veterinary relevance: none.
• Comparative pathology: NOT AVAILABLE. The barrier is conceptual as well as practical — the phenotype is defined by a developmental window and by symptoms (nausea, feeling unwell, awareness of retching) that are difficult to ascertain in an animal.
• Evolutionary conservation of mechanism: the substrate (central autonomic network, brainstem–forebrain homeostatic circuitry) is deeply conserved (PMID:26530629 describes the human structural connectome of this network and notes species differences: "a lateral forebrain bundle, whose connectivity is distinct from that of rodents and nonhuman primates, is the primary conduit for connections between the brainstem and medial temporal lobe"). The syndrome, however, is not known to be conserved.
• Zoonotic potential / cross-species susceptibility: NOT APPLICABLE (non-infectious).

15. Model Organisms

NO MODEL OF SeLEAS EXISTS. This is a firm negative and should be curated as one, with a KNOWLEDGE_GAP discussion attached.

Why no model exists

Three structural obstacles, worth recording because they explain the gap rather than merely noting it:

1. No causal gene to engineer. You cannot make a knock-in without a variant.
2. The defining feature is a developmental time-course (onset 3–6 human years, remission within 1–2 years, EEG normalization by 12–16 years). Mapping that window onto rodent development is non-trivial.
3. The cardinal symptom is emesis, and rodents cannot vomit. Mice and rats lack the brainstem emetic reflex circuitry required for vomiting — so the single most characteristic phenotype of this syndrome is unobservable in the default mammalian model. Any model would need a ferret, shrew, or non-human primate, none of which is a practical epilepsy-genetics platform.

Adjacent models that are not models of SeLEAS

Curate these only if the entry needs a HUMAN_MODEL_MISMATCH discussion — they are relevant background, not evidence for SeLEAS mechanism:

Model types, genetic models, phenotype recapitulation, applications, resources

• Model organism type: none available (mammalian, invertebrate, cellular, and in vitro all NOT AVAILABLE).
• Specific systems (iPSC, organoid, cell line): NOT AVAILABLE. No SeLEAS patient-derived iPSC line is registered in Cellosaurus or comparable resources.
• Induced models: NOT AVAILABLE.
• Genetic models (KO/KI/transgenic/conditional/humanized): NOT AVAILABLE.
• Phenotype recapitulation: N/A.
• Model limitations: see the three obstacles above.
• Research applications: the tractable research substrate for SeLEAS is human electrophysiology (longitudinal EEG, HFO quantification, source localization) and human functional imaging (the fMRI approach proposed but not yet executed by Zontek & Paprocka, PMID:35740751), not animal modeling.
• Model databases: MGI, RGD, ZFIN, IMPC, IMSR contain no SeLEAS-associated allele or phenotype annotation.

Appendix A — Summary of proposed dismech mechanistic_hypotheses

Because the mechanism is entirely hypothetical, I recommend curating it as competing hypotheses rather than a settled chain:

And suggested discussions:

• KNOWLEDGE_GAP — Are cognitive and behavioral comorbidities real, or an artifact of tertiary-referral bias? (attaches to the cognitive phenotype nodes; PMID:32608507 & PMID:31398558 vs PMID:20528983; commentary PMID:31909486)
• KNOWLEDGE_GAP — What is the molecular basis of the age-dependent hyperexcitability, and what causes remission? No omics, no model, no gene. Proposed experiments: longitudinal HFO/source-localization studies (PMID:37918221), the fMRI central-autonomic-network protocol proposed in PMID:35740751.
• KNOWLEDGE_GAP — Which drug, if any? No RCT has ever been performed (PMID:25202134 explicitly proposes the trial design).
• HUMAN_MODEL_MISMATCH — SCN1A mouse models exist but model Dravet/GEFS+, not SeLEAS; and rodents cannot vomit, so the cardinal phenotype is unmodellable in the standard platform.

Appendix B — Verified ontology term quick reference

All terms below were verified against live OLS4 (EBI) on 2026-08-05. Verify again with just validate-terms before committing — this list is a curation aid, not a substitute for the validator.

MONDO: MONDO:0020307 (Self-limited epilepsy with autonomic seizures)

HP: HP:0011154 · HP:0032740 · HP:0032755 · HP:0011159 · HP:0032761 · HP:0032773 · HP:0002013 · HP:0002018 · HP:0000980 · HP:0000961 · HP:0011499 · HP:0000549 · HP:0002384 · HP:0001279 · HP:0002133 · HP:0032861 · HP:0007334 · HP:0006813 · HP:0003781 · HP:0000020 · HP:0002315 · HP:0002104 · HP:0001662 · HP:0010841 · HP:0012016 · HP:0012557 · HP:0025644 · HP:0002353 · HP:0025373 · HP:0002270 · HP:0001328 · HP:0010794 · HP:0007018 · HP:0000739 · HP:0002373 (febrile seizure, for the family-history/antecedent phenotype)

GO: GO:0019228 · GO:0060078 · GO:0007214 · GO:0007215 · GO:0035725

CL: CL:0010012 · CL:0000598 · CL:0011005 · CL:0000127

UBERON: UBERON:0000955 · UBERON:0000956 · UBERON:0002021 · UBERON:0034891 · UBERON:0009835 · UBERON:0001876 · UBERON:0001898 · UBERON:0002298 · UBERON:0009050 · UBERON:0002162 · UBERON:0001759

CHEBI: CHEBI:3387 · CHEBI:6437 · CHEBI:7824 · CHEBI:39867 · CHEBI:31413 · CHEBI:6931 · CHEBI:49575 · CHEBI:32171

NCIT: NCIT:C15986 · NCIT:C64172 · NCIT:C264 · NCIT:C38054 · NCIT:C16809 · NCIT:C16959 · NCIT:C15747 · NCIT:C15240

HGNC: hgnc:10585 (SCN1A) — susceptibility only, rare families

Appendix C — Priority citations with verified abstract quotes

These are the highest-value evidence items for the entry. Every quote below is copied verbatim from the PubMed abstract as retrieved via NCBI E-utilities on 2026-08-05; each should still be run through just fetch-reference + just validate-references before committing.

Sources

• MONDO:0020307 via OLS4 (EMBL-EBI)
• ILAE — Self-Limited Epilepsy with Autonomic Seizures (SeLEAS): overview, EEG, imaging, genetics, diagnostic criteria, differential diagnoses (CC BY-SA 4.0; text last updated 2024-06-30)
• Specchio et al. 2022, ILAE classification of childhood-onset epilepsy syndromes — PMID:35503717
• Covanis 2006, Pediatrics — PMID:16950946
• Ferrie et al. 2006 consensus — PMID:16483404
• Ferrie et al. 2007, autonomic status epilepticus consensus — PMID:17442005
• Specchio et al. 2010, 93 consecutive patients — PMID:20528983
• Caraballo et al. 2007, 192 patients — PMID:17442007
• Weir et al. 2018, comparative incidence — PMID:29571057
• Koutroumanidis 2007, benign childhood system epilepsy — PMID:17441996
• Oguni 2023, reappraisal of interictal EEG — PMID:37660659
• Kivity et al. 2017, SCN1A spectrum — PMID:28192756
• Rudolf et al. 2020, exome sequencing in SFEC — PMID:32600977
• Taylor et al. 2008, benign occipital epilepsies twin/family study — PMID:18669497
• Kawakami et al. 2022, differentiating PS from acute encephalopathy — PMID:35153087
• Fonseca Wald et al. 2020, neurocognitive profile — PMID:32608507
• Mellish et al. 2015, UK practice survey and trial feasibility — PMID:25202134
• Fujita et al. 2023, scalp HFOs — PMID:37918221
• Berg et al. 2026, SeLEAS vs childhood migraine — PMID:42348808
• Zontek & Paprocka 2022, GI/autonomic symptoms and the central autonomic network — PMID:35740751
• Cooper et al. 2023, epilepsy syndromes in cerebral palsy — PMID:35871494
• Panayiotopoulos 2004, autonomic seizures and autonomic status epilepticus — PMID:15145296
• Graziosi et al. 2019, misdiagnosis and pitfalls — PMID:31369969
• Quito-Betancourt & Reyes Valenzuela 2023, self-limited focal epilepsies of childhood — PMID:37714124
• Self-Limited Focal Epilepsies in Childhood: How Many and How to Treat (Pediatric Reports, 2025)
• ClinicalTrials.gov API v2 — zero studies for "Panayiotopoulos" (retrieved 2026-08-05)
• Orphanet ORPHA:98815
• MedLink Neurology — Self-limited epilepsy with autonomic seizures